Michael Anthony Hollingsworth

Michael Anthony Hollingsworth's AcademicInfluence.com Rankings

Philosophy

#7611

World Rank

#10849

Historical Rank

Logic

#4657

World Rank

#5976

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Michael Anthony Hollingsworth's Degrees

PhD Biomedical Sciences University of California, San Francisco
Bachelors Biology Stanford University

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Michael Anthony Hollingsworth Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael Anthony Hollingsworth's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Tumour exosome integrins determine organotropic metastasis (2015) (3223)
Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver (2015) (1909)
Mucins in cancer: protection and control of the cell surface (2004) (1640)
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma (2015) (1232)
Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. (1999) (640)
Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro (2003) (611)
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. (2018) (538)
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers (2020) (475)
Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer (2008) (460)
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. (2003) (432)
Cloning and sequencing of a human pancreatic tumor mucin cDNA. (1990) (416)
A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns (2016) (399)
Cell surface-associated mucins in signal transduction. (2006) (395)
Patterns of somatic structural variation in human cancer genomes (2020) (377)
Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs (2015) (372)
Probiotics inhibit enteropathogenic E. coliadherence in vitro by inducing intestinal mucin gene expression. (1999) (338)
Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. (2002) (312)
Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis (2017) (298)
Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. (2005) (298)
Substrate Specificities of Three Members of the Human UDP-N-Acetyl-α-d-galactosamine:Polypeptide N-Acetylgalactosaminyltransferase Family, GalNAc-T1, -T2, and -T3* (1997) (286)
Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. (2001) (264)
MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. (2002) (244)
Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. (2006) (242)
Immature truncated O-glycophenotype of cancer directly induces oncogenic features (2014) (233)
Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. (1998) (231)
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. (2017) (231)
Serum antibodies to carbonic anhydrase I and II in patients with idiopathic chronic pancreatitis and Sjögren's syndrome. (1996) (228)
Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins (2007) (223)
Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring (2019) (220)
Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. (2010) (215)
A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma (2010) (214)
Oligosaccharides Expressed on MUC1 Produced by Pancreatic and Colon Tumor Cell Lines* (1997) (213)
Cloning of a Human UDP-N-Acetyl-α-d-Galactosamine:PolypeptideN-Acetylgalactosaminyltransferase That Complements Other GalNAc-Transferases in Complete O-Glycosylation of the MUC1 Tandem Repeat* (1998) (210)
Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH(2)-terminal kinase 1 and up-regulating N-cadherin expression. (2006) (209)
Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma (2017) (205)
Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer (2012) (191)
Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis (2011) (174)
Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. (2002) (174)
Cloning and Characterization of a Close Homologue of Human UDP-N-acetyl-α-d-galactosamine:Polypeptide N-Acetylgalactosaminyltransferase-T3, Designated GalNAc-T6 (1999) (168)
Functional Conservation of Subfamilies of Putative UDP-N-acetylgalactosamine:Polypeptide N-Acetylgalactosaminyltransferases inDrosophila, Caenorhabditis elegans, and Mammals (2002) (163)
Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia (2008) (160)
Early Detection of Sporadic Pancreatic Cancer (2015) (158)
The Lectin Domain of UDP-N-acetyl-d-galactosamine:PolypeptideN-acetylgalactosaminyltransferase-T4 Directs Its Glycopeptide Specificities* (2000) (157)
Pathologic Features of Mucin-producing Bile Duct Tumors: Two Histopathologic Categories as Counterparts of Pancreatic Intraductal Papillary-mucinous Neoplasms (2004) (153)
High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. (1999) (153)
Nuclear Association of the Cytoplasmic Tail of MUC1 and β-Catenin* (2003) (150)
MUC5B and MUC7 are differentially expressed in mucous and serous cells of submucosal glands in human bronchial airways. (1998) (149)
MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. (2008) (149)
Expression of MUC1, MUC2, MUC3 and MUC4 mucin mrnas in human pancreatic and intestinal tumor cell lines (1994) (145)
Aberrant Expression of Mucin Core Proteins and O-Linked Glycans Associated with Progression of Pancreatic Cancer (2013) (142)
Total pancreatectomy and islet autotransplantation in chronic pancreatitis: recommendations from PancreasFest. (2014) (140)
Identification of MUC1 proteolytic cleavage sites in vivo. (2001) (136)
The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice (2019) (132)
MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma‐mass forming type (2004) (132)
Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. (2003) (130)
Control of O-Glycan Branch Formation (1999) (130)
A novel human UDP‐N‐acetyl‐D‐galactosamine:polypeptide N‐acetylgalactosaminyltransferase, GalNAc‐T7, with specificity for partial GalNAc‐glycosylated acceptor substrates (1999) (120)
Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. (2019) (118)
The Prevalence and Nature of Glycan Alterations on Specific Proteins in Pancreatic Cancer Patients Revealed Using Antibody-Lectin Sandwich Arrays* (2009) (116)
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. (2017) (116)
Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy☆ (2017) (116)
RNA Interference Suppression of MUC1 Reduces the Growth Rate and Metastatic Phenotype of Human Pancreatic Cancer Cells (2006) (115)
Pathobiological Implications of MUC16 Expression in Pancreatic Cancer (2011) (112)
Advancing a clinically relevant perspective of the clonal nature of cancer (2011) (111)
A family of human beta3-galactosyltransferases. Characterization of four members of a UDP-galactose:beta-N-acetyl-glucosamine/beta-nacetyl-galactosamine beta-1,3-galactosyltransferase family. (1998) (110)
MUC2 gene expression is found in noninvasive tumors but not in invasive tumors of the pancreas and liver: its close relationship with prognosis of the patients. (1997) (109)
Image based detection and targeting of therapy resistance in pancreatic adenocarcinoma (2016) (109)
Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti‐adhesion molecule (2000) (107)
Platelet-derived growth factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells. (2007) (106)
Developmental expression of mucin genes MUC1 and MUC2. (1994) (105)
Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. (2003) (104)
The lectin domains of polypeptide GalNAc-transferases exhibit carbohydrate-binding specificity for GalNAc: lectin binding to GalNAc-glycopeptide substrates is required for high density GalNAc-O-glycosylation. (2007) (100)
Overexpression of MUC1 reconfigures the binding properties of tumor cells (2001) (99)
Induction of experimental autoimmune sialoadenitis by immunization of PL/J mice with carbonic anhydrase II. (1995) (95)
A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis (2007) (93)
A Regulatory Element in Intron 1 of the Cystic Fibrosis Transmembrane Conductance Regulator Gene (*) (1996) (92)
Microfluidic immunocapture of circulating pancreatic cells using parallel EpCAM and MUC1 capture: characterization, optimization and downstream analysis. (2014) (92)
A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study (2017) (89)
Phosphorylation of MUC1 by Met Modulates Interaction with p53 and MMP1 Expression* (2008) (86)
Differential Expression of Metabolic Genes in Tumor and Stromal Components of Primary and Metastatic Loci in Pancreatic Adenocarcinoma (2012) (85)
Human MUC4 mucin cDNA and its variants in pancreatic carcinoma. (2000) (82)
Notch2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells (2005) (81)
Metastatic cancers promote cachexia through altered zinc homeostasis in skeletal muscle (2018) (81)
ADH‐1 suppresses N‐cadherin‐dependent pancreatic cancer progression (2008) (77)
Cyclin-Dependent Kinase 5 Is Amplified and Overexpressed in Pancreatic Cancer and Activated by Mutant K-Ras (2011) (77)
The human homologue of the RNA polymerase II-associated factor 1 (hPaf1), localized on the 19q13 amplicon, is associated with tumorigenesis (2006) (76)
Overexpression of GalNAc-transferase GalNAc-T3 Promotes Pancreatic Cancer Cell Growth (2011) (76)
The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF (2010) (74)
CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. (1998) (72)
Loss of fibulin-2 expression is associated with breast cancer progression. (2007) (71)
MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion. (2007) (69)
A Family of Human β3-Galactosyltransferases (1998) (66)
Polypeptide core of a human pancreatic tumor mucin antigen. (1990) (66)
Influence of acceptor substrate primary amino acid sequence on the activity of human UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase. Studies with the MUC1 tandem repeat. (1994) (65)
N-acetylgalactosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts. (1994) (64)
Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer (2013) (63)
Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. (2013) (63)
Expression of three UDP-N-acetyl-alpha-D-galactosamine:polypeptide GalNAc N-acetylgalactosaminyltransferases in adenocarcinoma cell lines. (1997) (62)
Regulation of Aerobic Glycolysis by microRNAs in Cancer. (2011) (62)
Extracellular MUC 3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro (2003) (62)
Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer. (2016) (61)
Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer (2013) (61)
Expression of Core 2 β-1,6-N-Acetylglucosaminyltransferase in a Human Pancreatic Cancer Cell Line Results in Altered Expression of MUC1 Tumor-associated Epitopes* (1999) (61)
P-selectin expression in a metastatic pancreatic tumor cell line (SUIT-2). (1997) (59)
Substrate Specificities of Three Members of the Human UDP-N-Acetyl-a-D-galactosamine : Polypeptide N-Acetylgalactosaminyltransferase Family (1997) (59)
Calcium-activated chloride conductance in a pancreatic adenocarcinoma cell line of ductal origin (HPAF) and in freshly isolated human pancreatic duct cells (1998) (58)
Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. (2018) (58)
MUC4 expression is regulated by cystic fibrosis transmembrane conductance regulator in pancreatic adenocarcinoma cells via transcriptional and post-translational mechanisms (2007) (57)
Intracellular CD24 inhibits cell invasion by posttranscriptional regulation of BART through interaction with G3BP. (2011) (57)
The role of the SEA (sea urchin sperm protein, enterokinase and agrin) module in cleavage of membrane‐tethered mucins (2005) (56)
Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. (2020) (56)
Structural effects of O-glycosylation on a 15-residue peptide from the mucin (MUC1) core protein. (2000) (55)
Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility (2016) (52)
Functional Conservation of Subfamilies of Putative UDP-N-acetylgalactosamine:Polypeptide N-Acetylgalactosaminyltransferases in Drosophila, Caenorhabditis elegans, and Mammals ONE SUBFAMILY COMPOSED OF l(2)35Aa IS ESSENTIAL IN DROSOPHILA* (2002) (50)
Conformational studies on the MUC1 tandem repeat glycopeptides: implication for the enzymatic O-glycosylation of the mucin protein core. (2003) (50)
Macrophage-Derived Neuropilin-2 Exhibits Novel Tumor-Promoting Functions. (2018) (49)
Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling) (2016) (49)
The contribution of tandem repeat number to the O-glycosylation of mucins. (2003) (47)
Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation (2019) (45)
MicroRNA-200c Modulates the Expression of MUC4 and MUC16 by Directly Targeting Their Coding Sequences in Human Pancreatic Cancer (2013) (43)
Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin. (1997) (42)
Sex differences in oncogenic mutational processes (2019) (41)
Transfection of the human Muc 1 mucin gene into a poorly differentiated human pancreatic tumor cell line, Panc1: integration, expression and ultrastructural changes. (1991) (41)
MUC1 mucin mRNA expression in cultured human nasal and bronchial epithelial cells. (1992) (41)
Thomsen-Friedenreich antigen expression in gastric carcinomas is associated with MUC1 mucin VNTR polymorphism. (2005) (41)
Molecular cloning and sequence analysis of the human ribosomal protein S16. (1991) (41)
The N-Terminal Domain of G3BP Enhances Cell Motility and Invasion by Posttranscriptional Regulation of BART (2011) (40)
MUC4-Mediated Regulation of Acute Phase Protein Lipocalin 2 through HER2/AKT/NF-κB Signaling in Pancreatic Cancer (2013) (39)
Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas (2016) (38)
The cystic fibrosis transmembrane conductance regulator as a marker of human pancreatic duct development. (1997) (38)
In vivo glycosylation of mucin tandem repeats. (2001) (38)
MUC1 Is a Counter-Receptor for Myelin-Associated Glycoprotein (Siglec-4a) and Their Interaction Contributes to Adhesion in Pancreatic Cancer Perineural Invasion (2007) (38)
Targeting the tumor core: hypoxia-responsive nanoparticles for delivery of chemotherapy to pancreatic tumors. (2020) (38)
CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity. (2007) (38)
The lymphatic system and pancreatic cancer. (2016) (37)
MUC1 Regulates Expression of Multiple microRNAs Involved in Pancreatic Tumor Progression, Including the miR-200c/141 Cluster (2013) (37)
Molecular pathology of early pancreatic cancer. (2010) (37)
Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma (2020) (36)
Identification of carbonic anhydrase IV and VI mRNA expression in human pancreas and salivary glands. (1999) (36)
Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1) (2004) (35)
Carbonic Anhydrase in Human Pancreas: Hypotheses for the Pathophysiological Roles of CA Isozymes (1999) (35)
The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response (2019) (34)
Structural analysis of peptide substrates for mucin-type O-glycosylation. (1998) (34)
Erratum: MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer (Cancer Cell (2017) 32(1) (71–87.e7) (S1535610817302544) (10.1016/j.ccell.2017.06.004)) (2017) (33)
Predicted Prognosis of Patients with Pancreatic Cancer by Machine Learning (2020) (33)
MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells (Cancer Research (April 1, 2008) 68(2065-2070)) (2008) (33)
Overexpression of Ecdysoneless in Pancreatic Cancer and Its Role in Oncogenesis by Regulating Glycolysis (2012) (33)
Indocyanine green loaded hyaluronan-derived nanoparticles for fluorescence-enhanced surgical imaging of pancreatic cancer. (2018) (31)
Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens (2015) (31)
SIRT1–NOX4 signaling axis regulates cancer cachexia (2020) (31)
Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinoma (2014) (31)
Loss of E-cadherin and epithelial to mesenchymal transition is not required for cell motility in tissues or for metastasis (2014) (31)
Functional Heterogeneity of Colonic Adenocarcinoma Mucins for Inhibition of Entamoeba histolytica Adherence to Target Cells 1 (1998) (30)
Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia. (2020) (30)
A nuclear factor that binds purine-rich, single-stranded oligonucleotides derived from S1-sensitive elements upstream of the CFTR gene and the MUC1 gene. (1994) (30)
MUC1 regulates cyclin D1 gene expression through p120 catenin and β-catenin (2014) (29)
Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses. (2005) (29)
Expression of core 3 synthase in human pancreatic cancer cells suppresses tumor growth and metastasis (2013) (29)
MUC4 mucin expression in human pancreatic tumours is affected by organ environment: the possible role of TGFβ2 (2004) (29)
Relevance of MUC1 mucin variable number of tandem repeats polymorphism in H pylori adhesion to gastric epithelial cells. (2008) (28)
Cholecystokinin A and B receptor mRNA expression in human pancreas. (1999) (28)
Expression of UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase isozymes T1 and T2 in human colorectal cancer (2000) (28)
The Human RNA Polymerase II-Associated Factor 1 (hPaf1): A New Regulator of Cell-Cycle Progression (2009) (27)
Sulfation modulates the targeting properties of hyaluronic acid to P-selectin and CD44. (2020) (27)
Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers (2016) (27)
MUC1 expressed in PanC1 cells decreases adhesion to type 1 collagen but increases contraction in collagen lattices. (1996) (27)
Tumor suppression by collagen XV is independent of the restin domain. (2012) (27)
Interactions between MUC1 and p120 catenin regulate dynamic features of cell adhesion, motility, and metastasis. (2014) (27)
Alteration in expression of MUC2 and MUC3 mRNA levels in HT29 colonic carcinoma cells. (1994) (26)
Complete Suppression of Tumor Formation by High Levels of Basement Membrane Collagen (2007) (26)
Targeting the NF-κB and mTOR Pathways with a Quinoxaline Urea Analog That Inhibits IKKβ for Pancreas Cancer Therapy (2013) (25)
Amyloid precursor-like protein 2 (APLP2) affects the actin cytoskeleton and increases pancreatic cancer growth and metastasis (2014) (25)
Passively transferred anti‐MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice (1999) (25)
Radiomics-Based Outcome Prediction for Pancreatic Cancer Following Stereotactic Body Radiotherapy (2020) (23)
Organ-specific pancreatic tumor growth properties and tumor immunity (1999) (23)
Influence of organ site and tumor cell type on MUC1-specific tumor immunity. (2001) (23)
High collagenolytic activity in spontaneously highly metastatic variants derived from a human pancreatic cancer cell line (SUIT-2) in nude mice (2004) (23)
Nerve Growth Factor Regulates Neurolymphatic Remodeling during Corneal Inflammation and Resolution (2014) (23)
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle (2018) (22)
T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1. (2005) (21)
Potential for H-DNA in the Human MUC1 Mucin Gene Promoter* (1996) (21)
MUC1 extracellular domain confers resistance of epithelial cancer cells to anoikis (2014) (21)
Upregulation of ZIP14 and Altered Zinc Homeostasis in Muscles in Pancreatic Cancer Cachexia (2019) (21)
Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy (2017) (21)
What a fish can learn from a mouse: principles and strategies for modeling human cancer in mice. (2009) (21)
SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells (2016) (21)
Impact of MUC1 Mucin Downregulation in the Phenotypic Characteristics of MKN45 Gastric Carcinoma Cell Line (2011) (20)
CFTR expression does not influence glycosylation of an epitope-tagged MUC1 mucin in colon carcinoma cell lines. (1999) (20)
Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas (2020) (20)
Spatiotemporal Proteomic Analyses during Pancreas Cancer Progression Identifies Serine/Threonine Stress Kinase 4 (STK4) as a Novel Candidate Biomarker for Early Stage Disease* (2014) (20)
In vitro pancreatic ductal cell carcinogenesis (1997) (19)
Control of mucin-type o-glycosylation: O-glycan occupancy is directed by substrate specificities of polypeptide GalNAc-transferases (2008) (18)
Relevance of amyloid precursor-like protein 2 C-terminal fragments in pancreatic cancer cells (2012) (18)
Advances in Biomedical Imaging, Bioengineering, and Related Technologies for the Development of Biomarkers of Pancreatic Disease: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases and National Institute of Biomedical Imaging and Bioengineering Workshop (2015) (18)
Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma (2019) (18)
MUC1-specific anti-tumor responses: molecular requirements for CD4-mediated responses. (2002) (18)
Reflections on MUC1 glycoprotein: the hidden potential of isoforms in carcinogenesis (2016) (18)
Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors (2018) (17)
MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans. (2021) (16)
Isoforms of MUC16 Activate Oncogenic Signaling Through EGF Receptors to Enhance the Progression of Pancreatic Cancer. (2020) (16)
Purification and characterization of a human pancreatic adenocarcinoma mucin. (2002) (16)
CD73 Induces GM-CSF/MDSC-mediated Suppression of T cells to Accelerate Pancreatic Cancer Pathogenesis (2021) (15)
CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax (2019) (15)
Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal. (2020) (14)
Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines (2002) (14)
Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma (2019) (14)
Using Quantitative Imaging for Personalized Medicine in Pancreatic Cancer: A Review of Radiomics and Deep Learning Applications (2022) (13)
Altered expression of sialylated carbohydrate antigens in HT29 colonic carcinoma cells (1998) (13)
A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer (2019) (13)
Contribution of the MUC 1 Tandem Repeat and Cytoplasmic Tail to Invasive and Metastatic Properties of a Pancreatic Cancer Cell Line 1 (2003) (13)
TET1-mediated DNA hypomethylation regulates the expression of MUC4 in lung cancer (2017) (13)
Mucin family of glycoproteins (2013) (13)
MUC 4 Mucin Interacts with and Stabilizes the HER 2 Oncoprotein in Human Pancreatic Cancer Cells (2008) (12)
Expression of the human MUC1 mucin cDNA in a hamster pancreatic tumor cell line HP-1 (1992) (12)
A simple, effective method for the construction of subtracted cDNA libraries. (1991) (12)
Chloride-bicarbonate exchangers in the human fetal pancreas. (1999) (12)
Human Muc 1 mucin gene expression in the fetal pancreas. (1992) (12)
Identification of FRA-1 as a novel player in pancreatic cancer in cooperation with a MUC1: ERK signaling axis (2016) (11)
MZF-1 and DbpA interact with DNase I hypersensitive sites that correlate with expression of the human MUC1 mucin gene. (2005) (11)
A Potential H-DNA Element in the MUC1 Promoter Does Not Influence Transcription* (1996) (11)
Tapasin Decreases Immune Responsiveness to a Model Tumor Antigen (2004) (10)
Alu‐polymerase chain reaction genomic fingerprinting technique identifies multiple genetic loci associated with pancreatic tumourigenesis (1997) (10)
Collagen fiber regulation in human pediatric aortic valve development and disease (2021) (10)
Methionine oxidation activates pyruvate kinase M2 to promote pancreatic cancer metastasis. (2022) (10)
Isolation and characterization of a complementary DNA (PD-1) differentially expressed by human pancreatic ductal cell tumors. (1991) (10)
Expression of the human mucin gene, Muc 1, in normal tissues and metastatic pancreatic tumors (1991) (9)
Antigens expressed on NIH 3T3 cells following transformation with DNA from human pancreatic tumor. (1986) (9)
Heme Oxygenase-1 Inhibition Potentiates the Effects of Nab-Paclitaxel-Gemcitabine and Modulates the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma (2021) (9)
Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis. (2021) (9)
Enzymatic and chemical probing of an S1 nuclease-sensitive site upstream from the human CFTR gene. (1994) (8)
1st year practicals: Their role in developing future bioscientists (2008) (8)
Chemical Genetic Screens Identify Kinase Inhibitor Combinations that Target Anti-Apoptotic Proteins for Cancer Therapy. (2018) (8)
Invasive phenotype induced by low extracellular pH requires mitochondria dependent metabolic flexibility. (2020) (8)
Effect of MUC1/β-catenin interaction on the tumorigenic capacity of pancreatic CD133+ cells (2016) (8)
Antigens of Normal and Malignant Human Exocrine Pancreatic Cells (1985) (8)
Effects of interobserver and interdisciplinary segmentation variabilities on CT-based radiomics for pancreatic cancer (2021) (8)
Evaluation of MUC6 mucin tandem repeats. (2005) (7)
Tumor Biomarker In-Solution Quantification, Standard Production, and Multiplex Detection (2021) (7)
The glycoprotein mucin‐1 negatively regulates GalNAc transferase 5 expression in pancreatic cancer (2019) (7)
Mucin 5AC-mediated CD44/ITGB1 clustering mobilizes adipose-derived mesenchymal stem cells to modulate pancreatic cancer stromal heterogeneity. (2022) (7)
Proteins Expressed by Pancreatic Duct Cellsand Their Relatives (1999) (6)
Tuned near infrared fluorescent hyaluronic acid conjugates for delivery to pancreatic cancer for intraoperative imaging (2020) (6)
Suppression of pancreatic cancer liver metastasis by secretion-deficient ITIH5 (2020) (6)
The small heat shock protein αA-crystallin negatively regulates pancreatic tumorigenesis (2016) (6)
Visceral adipose tissue remodeling in pancreatic ductal adenocarcinoma cachexia: the role of activin A signaling (2022) (6)
Development of a MUC16-Targeted Near-Infrared Fluorescent Antibody Conjugate for Intraoperative Imaging of Pancreatic Cancer (2020) (5)
Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns (2016) (5)
Phosphorylation of MUC 1 by Met Modulates Interaction with p 53 and MMP 1 Expression * (2017) (5)
DU-PAN-2, mucin type differentiation antigen of normal and malignant pancreatic ductal cells. (1989) (5)
Age-related increases in mitogenic responses and natural immunity to a syngeneic fibrosarcoma in rats (1981) (5)
ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody (2021) (5)
Cell and molecular biology of pancreatic carcinoma : recent developments in research and experimental therapy (1999) (5)
Induction of pancreatic neoplasia in the KRAS/TP53 Oncopig (2020) (4)
Porcine pancreatic ductal epithelial cells transformed with KRASG12D and SV40T are tumorigenic (2021) (4)
Differential expression profile of CXC-receptor-2 ligands as potential biomarkers in pancreatic ductal adenocarcinoma. (2022) (4)
The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors (2021) (4)
Identification of two novel elements involved in human MUC1 gene expression in vivo (2002) (4)
Abstract 4503: A small molecule glycomimetic antagonist of E-selectin (GMI-1271) prevents pancreatic tumor metastasis and offers a novel treatment for improved efficacy of chemotherapy (2014) (4)
Autoantigens of Sjögren’s Syndrome (1999) (4)
Quantification of tumor stroma as a biomarker in pancreatic adenocarcinoma. (2015) (3)
Generation of tumorigenic porcine pancreatic ductal epithelial cells: toward a large animal model of pancreatic cancer (2018) (3)
Truncated O-Glycan-Bearing MUC16 Enhances Pancreatic Cancer Cells Aggressiveness via α4β1 Integrin Complexes and FAK Signaling (2022) (3)
Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring (2019) (3)
Differences in spleen suppressor cell content in rats with progressing and regressing tumors. (1982) (3)
Abstract 425: A small molecule glycomimetic antagonist of E-selectin and CXCR4 (GMI-1359) prevents pancreatic tumor metastasis and improves chemotherapy (2015) (3)
Met receptor inhibitor SU11274 localizes in the endoplasmic reticulum. (2018) (3)
Changes in spleen cell proliferative responses and resistance to syngeneic tumor challenge in aging NBR rats (1983) (3)
Flt3 ligand delivered in a pluronic formulation prolongs the survival of mice with orthotopic pancreatic adenocarcinoma. (2007) (3)
Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy (2020) (3)
Plexin-B3 Regulates Cellular Motility, Invasiveness, and Metastasis in Pancreatic Cancer (2021) (3)
Comparison of ras-responsive gene enhancers in pancreatic tumor cells that express either wild-type or mutant K-ras. (2009) (2)
vitro by inducing intestinal mucin gene expression adherence in E. coli Probiotics inhibit enteropathogenic (2016) (2)
Mucin-1 is required for Coxsackie Virus B3-induced inflammation in pancreatitis (2019) (2)
Comparative phenotypes of peripheral blood and spleen cells from cancer patients. (2020) (2)
Inhibition of the Receptor for Advanced Glycation End Products Enhances the Cytotoxic Effect of Gemcitabine in Murine Pancreatic Tumors (2021) (2)
Identification of two novel elements involved in human MUCI gene expression in vivo. (2002) (2)
Expression of UDP-GalNAc: Polypeptide N-acetyl-galactos-aminyltransferase in human gastric cancer (1998) (2)
Machine learning analyses of highly-multiplexed immunofluorescence identifies distinct tumor and stromal cell populations in primary pancreatic tumors. (2022) (2)
A Rapid and Sensitive Bioanalytical LC-MS/MS Method for the Quantitation of a Novel CDK5 Inhibitor 20-223 (CP668863) in Plasma: Application to in vitro Metabolism and Plasma Protein Binding Studies. (2020) (2)
Summary of a meeting: Workshop on cell and molecular biology of pancreatic cancer (1993) (2)
MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2 Associated Cell Adhesion. (2022) (2)
1 DISTINCT MUTATIONAL SIGNATURES ARE ASSOCIATED WITH CORRELATES OF 1 INCREASED IMMUNE ACTIVITY IN PANCREATIC DUCTAL ADENOCARCINOMA 2 3 (2016) (1)
Substituent Effects Impact Surface Charge and Aggregation of Thiophenol-Labeled Gold Nanoparticles for SERS Biosensors (2022) (1)
Three-Dimensional Printed Abdominal Imaging Windows for In Vivo Imaging of Deep-Lying Tissues (2022) (1)
NMR-based Structural Studies of the Glycosylated MUC1 Tandem Repeat Peptide (2004) (1)
Investigational strategies for detection and intervention in early-stage pancreatic cancer (1994) (1)
MUC1-CT regulates UDP: polypeptide N-Acetylgalactosaminyltransferases (ppGalNAc- Ts) expression in pancreatic cancer (2016) (1)
Abstract 1554: Rosiglitazone and Gemcitabine combination therapy reduces immune suppression and modulates T cell populations in pancreatic cancer (2012) (1)
Abstract 991: Regulation of glucose metabolism by HIF in pancreatic cancer (2011) (1)
Translational implications of molecular genetics for early diagnosis of pancreatic cancer (2013) (1)
Abstract 2308: MUC1 modulation of E-cadherin through miR-200c and ZEB1 (2012) (1)
Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
Modulation in the expression of intestinal MUC3 mucin by non-pathogenic probiotic microbes (2000) (1)
Paraneoplastic Autoimmune Reactions (1999) (1)
Preclinical Evaluation of a Humanized, Near-Infrared Fluorescent Antibody for Fluorescence-Guided Surgery of MUC16-Expressing Pancreatic Cancer. (2022) (1)
Evaluation of technique for autotransplantation of the spleen in dogs. (1983) (1)
Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients. (2022) (1)
Imaging , Diagnosis , Prognosis MUC 4-MediatedRegulation of Acute PhaseProtein Lipocalin 2 through HER 2 / AKT / NFk B Signaling in Pancreatic Cancer (2014) (1)
Abstract 813: Development of a porcine model for pancreatic cancer (2017) (1)
Angiogenesis , Metastasis , and the Cellular Microenvironment The N-Terminal Domain of G 3 BP Enhances Cell Motility and Invasion by Posttranscriptional Regulation of BART (2011) (1)
Abstract A69: TruncatedO-glycans enhance tumorigenicity of pancreatic tumors. (2012) (0)
Abstract 1420: Novel expansion of CD8+PD1+ spleen cells for therapeutic intent in pancreatic adenocarcinoma cancer (2019) (0)
Alu‐polymerase chain reaction genomic fingerprinting technique identifies multiple genetic loci associated with pancreatic tumourigenesis (1997) (0)
Carbonic anhydrase IV and VI mRNA expression in human pancreas (1998) (0)
Suppression of pancreatic cancer liver metastasis by secretion-deficient ITIH5 (2020) (0)
Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
Abstract 4010: Significant roles of p120 catenin and MUC1 in promoting invasive behavior of pancreatic cancer cells (2011) (0)
Glycan alterations on serum mucins in pancreatic cancer patients (2008) (0)
A murine model for human pancreatic cancer: Orthotopic injection of syngeneic pancreatic tumor cells (1998) (0)
PNAS Plus Significance Statements (2014) (0)
#earlydetection: Leveraging social media to recruit individuals at increased-risk of pancreas cancer for an early detection study. (2019) (0)
In vitro kinetic analysis of cellular anti-MUC1 immune responses in MUC1 transgenic mice (1998) (0)
Structural analysis of peptide substrates for O-glycosylation (2002) (0)
Abstract LB-225: Liquid biopsies identify trunk mutations and reflect multiple tumors in a patient (2018) (0)
Posttranslational processing of MUC1 by pancreatic tumors (1994) (0)
A novel adhesion factor produced by hamster pancreatic cancer cell line is effective on normal and carcinoma cell lines of different species (1995) (0)
Abstract PR15: A novel NK cell-targeted therapeutic strategy against pancreatic cancer (2020) (0)
Abstract 2883: The expression and potential role of MUC7 in pancreatic adenocarcinoma. (2012) (0)
Abstract 2720: Glycosylation of Mucins Expressed in Pancreatic Adenocarcinoma (2010) (0)
Monoclonal antibodies to human antigens expressed on NIH 3T3 cells following transfection with human pancreatic tumor cell DNA (1985) (0)
RAGE inhibitors and gemcitabine: an effective combination to attenuate pancreatic cancer (2018) (0)
Cancer Cell Line Tail to Invasive and Metastatic Properties of a Pancreatic Contribution of the MUC 1 Tandem Repeat and Cytoplasmic Updated (2003) (0)
Abstract 5220: Inflamed and wound recovered tumor microenvironment contributions to lymphatic-mediated metastasis (2015) (0)
Small-molecule IKKβ activation modulator (IKAM) targets MAP3K1 and inhibits pancreatic tumor growth (2022) (0)
654 Analysis of IDO-1 expression on dendritic cells and factors influencing its up- and downregulation in pancreatic cancer (2021) (0)
Abstract 508: Identification of FRA-1 as a potential driver of pro-invasive properties in pancreatic cancer in conjunction with MUC1 (2015) (0)
Abstract LB-429: Dormant cancer cells contribute to residual disease in a mouse model for reversible pancreatic cancer (2012) (0)
Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
Abstract PO-037: Development of an RGD CRISPR-modified Clostridium novyi NT spores as an intravenous oncotherapy (2021) (0)
A phase II study of neodjuvant chemoimmunotherapy followed by stereotactic radiotherapy/nelfinavir in patients with locally advanced CA125 expressing pancreatic adenocarcinoma. (2018) (0)
Identification of two novel elements involved in human MUC 1 gene expression in vivo (2002) (0)
Abstract 5152: Targeting HIF1α-mediated metabolic alterations in pancreatic cancer (2012) (0)
Inflammatory and immune effects on tumor progression (2021) (0)
Fetal Pancreas (2006) (0)
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
Preface (1999) (0)
Helper factor(s) generated by tumor-immune rats for lymphoproliferative responses to syngeneic tumor cells. (1984) (0)
Abstract P2-10-18: Deciphering racial disparities in breast cancer collagen reorganization by targeted extracellular matrix proteomics (2020) (0)
Abstract 2449: Pancreatic cancer tumor initiating cells are marked by the presence of a primary cilium (2011) (0)
Composition and method for enhancing the immune response of antigen-presenting cells (1996) (0)
Abstract A30: AR20.5-based novel immunotherapy for pancreatic cancer (2017) (0)
Relevance of MUC1 mucin variable number of tandem repeats polymorphism in Helicobacter pylori adhesion to gastric epithelial cells (2007) (0)
Abstract A82: Virtual microdissection reveals tumor specific heterogeneity in pancreatic cancer (2015) (0)
DU-PAN-2, A Clinically Useful Mucin Marker of Differentiation of Pancreatic and Other Ductal Cells and Their Tumors (1992) (0)
T1724 Characterization of MUC1 Signaling Pathways in Pancreatic Cancer Stem Cells (2010) (0)
ALTERATION IN THE EXPRESSION MUC2 AND MUC3 mRNA LEVELS IN HT29 CELLS INCUBATED WITH A PROBIOTIC AGENT (1998) (0)
Abstract 1575: A dual immunostimulatory strategy for pancreatic cancer treatment: MUC1 cytoplasmic tail peptide therapeutic vaccine with adjuvant TLR3 agonist poly(I:C12U) (2012) (0)
Mucins as contrast agent targets for fluorescence-guided surgery of pancreatic cancer. (2023) (0)
MUC16 as a potential target for the surgical detection of pancreatic cancer (2020) (0)
DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation (2023) (0)
Tumor and Stem Cell Biology Interactions between MUC 1 and p 120 Catenin Regulate Dynamic Features of Cell Adhesion , Motility , and Metastasis (2014) (0)
Radiomics-Based Survival and Recurrence Prediction for Pancreatic Cancer Following Stereotactic Body Radiotherapy (2020) (0)
Mucin-1 is required for Coxsackie Virus B3-induced inflammation in pancreatitis (2019) (0)
Engrailed-1 Promotes Pancreatic Cancer Metastasis (2023) (0)
Abstract LB-206: A novel scaffold that targets the IKK complex (2011) (0)
PREVENTING OR TREATING CANCER (2017) (0)
Abstract 1304: Specific MUC1 isoforms function to regulate gene expression and tumor growth in pancreatic cancer (2012) (0)
Abstract 1493: Analysis of fibrosis and stromal components in metastatic pancreatic cancer (PC) autopsy specimens (2012) (0)
Uncovering Tumor-Promoting Roles of Activin A in Pancreatic Ductal Adenocarcinoma. (2023) (0)
Abstract 5077: Signaling through the cytoplasmic tail of MUC1 directly activates transcription of the metastasis promoting growth factor CTGF in pancreatic adenocarcinoma (2010) (0)
N-Cadherin Expression-Terminal Kinase 1 and Up-regulating 2 Activating c-Jun NH Collagen I Promotes Metastasis in Pancreatic Cancer (2006) (0)
Increased expression of ezrin is related with the metastatic potential of human pancreatic adenocarcinoma (2000) (0)
Surgical imaging of pancreatic cancer using polysaccharide-delivered near infrared fluorophores (2019) (0)
Activated Stroma Differences at Metastatic Sites in Pancreatic Cancer (2016) (0)
Abstract 5391: Rosiglitazone and Gemcitabine combination therapy limits tumor progression and prolongs survival in pancreatic adenocarcinoma (2010) (0)
The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response—Response (2021) (0)
Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
Abstract 2384: A novel mouse model for the study of c-MYC during initiation and progression of pancreatic ductal adenocarcinoma (2011) (0)
Markers for detecting early pancreatic cancer: Summary (1994) (0)
Serum autoantibodies reactive with carbonic anhydrase II in patients with chronic pancreatitis and Sjögren's syndrome (1995) (0)
Abstract 881: Identification of autoantibody biomarkers to wild-type and mutant p53 in pancreatic and ovarian cancer (2014) (0)
Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring (2021) (0)
PROFILING GLYCAN STRUCTURES ON MUCINS IN THE SERA OF PANCREATIC CANCER PATIENTS USING ANTIBODY ARRAYS: CANCER-ASSOCIATED VARIATION AND POTENTIAL DISEASE MARKERS (2007) (0)
Illuminating histidine phosphorylation in the pancreatic tumor microenvironment (2022) (0)
Abstract 4049: Cellular phenotypes of spleen cells in cancer patients targeted for adoptive cellular therapy (2019) (0)
Abstract 5391: MUC1 and HIF-1α signaling interactions modulate glucose flux in pancreatic cancer. (2013) (0)
OVEREXPRESSION OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN (IGFBP)-4 RESULTS IN INCREASED PROLIFERATION RATE AND MUC3 EXPRESSION (1995) (0)
Abstract 5517: Polymeric nanogel-based treatment regimen for enhanced efficacy and sequential administration of synergistic drug combination in pancreatic cancer (2015) (0)
Sonic hedgehog promotes tumor growth, metastasis and desmoplasia in pancreatic cancer (2007) (0)
Corrigendum (2016) (0)
Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring (2021) (0)
Abstract 4102: Surgical imaging of pancreatic cancer using near infrared fluorescent hyaluronic acid nanomaterials (2018) (0)
Effect Of Interobserver And Interdisciplinary Segmentation Variability On Radiomic Features For Pancreatic Cancer (2020) (0)
Lrig1 Regulates Epithelial to Mesenchyme Transition (EMT) in Pancreatic Duct Glands (PDG), an Epithelial Stem Cell Compartment Important in Regeneration and Cancer (2020) (0)
Abstract CN09-04: Molecular approaches to early detection of pancreatic cancer (2010) (0)
Abstract 4942: Metastatic tumor migration in lymphatic vessels revealed by real-time intravital imaging (2014) (0)
Abstract 902: A small molecule glycomimetic antagonist of E-selectin and CXCR4 (GMI-1359) delays pancreatic tumor metastasis and significantly alters the pancreatic tumor microenvironment (2016) (0)
RGWAS: A Novel Genome-Wide Association Study to Link Genomics to Radiomics for Pancreatic Cancer (2022) (0)
Winter 2-20-2004 NMR-based Structural Studies of the Glycosylated MUC 1 Tandem Repeat Peptide (2004) (0)
Abstract A27: Exploring the role of glycosylation in pancreatic disease (2018) (0)
A novel ribonucleoprotein complex defined by monoclonal antibodies to NIH 3T3 cells transfected with human pancreatic adenocarcinoma DNA. (1990) (0)
MOLECULAR CANCER THERAPEUTICS | LARGE MOLECULE THERAPEUTICS IgE-BasedTherapeuticCombinationEnhancesAntitumor Response in Preclinical Models of Pancreatic Cancer (2021) (0)
Transgenic Mice Undetectable In Vitro and Is Absent in MUC 1 Tumor Immunity In Vivo That Is Lymphocytes Provide MUC 1-Specific + CD 4 Hollingsworth (1998) (0)
Suppression of polyclonal, tumor cell and alloantigen-induced proliferation: identification of cyclooxygenase pathway dependent and independent mechanisms. (1984) (0)
IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer (2021) (0)
Abstract 895: Glycopeptides in pancreatic adenocarcinoma (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michael Anthony Hollingsworth?

Michael Anthony Hollingsworth is affiliated with the following schools:

Michael Anthony Hollingsworth's Academic­Influence.com Rankings